Accelerate Diagnostics Inc (NASDAQ:AXDX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Accelerate Diagnostics Inc is an in vitro diagnostics company, dedicated in providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Accelerate Diagnostics Inc has a market cap of $1.16 billion; its shares were traded at around $21.38 with and P/S ratio of 205.61.
For the last quarter Accelerate Diagnostics Inc reported a revenue of $1.82 million, compared with the revenue of $2.12 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $5.67 million, an increase of 35.7% from last year. For the last five years Accelerate Diagnostics Inc had an average revenue growth rate of 171.6% a year.
The reported loss per diluted share was $1.62 for the year, compared with the loss per share of $1.01 in the previous year. The Accelerate Diagnostics Inc had an operating margin of -1417.44%, compared with the operating margin of -1536.61% a year before. The 10-year historical median operating margin of Accelerate Diagnostics Inc is -1479.11%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, Accelerate Diagnostics Inc has the cash and cash equivalents of $66.3 million, compared with $28.5 million in the previous year. The long term debt was $120.1 million. Accelerate Diagnostics Inc has a financial strength rank of 5 (out of 10).
At the current stock price of $21.38, Accelerate Diagnostics Inc is traded at 34.6% discount to its historical median P/S valuation band of $32.70. The P/S ratio of the stock is 205.61, while the historical median P/S ratio is 314.47. The stock lost 18.71% during the past 12 months.
For the complete 20-year historical financial data of AXDX, click here.
No comments:
Post a Comment